<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02989025</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0029</org_study_id>
    <nct_id>NCT02989025</nct_id>
  </id_info>
  <brief_title>Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia</brief_title>
  <acronym>PROGRESS</acronym>
  <official_title>Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia-The PROGRESS Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Babbette Lamarca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn if giving 17-hydroxyporgesterone caproate (17 OHPC) to
      mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby
      outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The OBGYN house and attending staff on duty caring for the patient will determine
      appropriateness for study inclusion. The treating physician will then immediately contact the
      MFM fellow on call and Research Division personnel to facilitate the initiation of study
      procedures, including the consent process and baseline blood tests. Once enrolled with
      informed consent, the participant will receive 17 OHPC, 250mg IM to be given at admission and
      every 7 days thereafter. Blood sampling of approximately 1-2 teaspoons each will be collected
      at baseline immediately prior to administration of 17 OHPC, then 24 hours (+-2hrs). After the
      first 24 hours, blood samples will be collected every 72 hrs until delivery and again 24hrs
      (+- 2hrs) after delivery. Placentas will be collected at delivery and the investigators will
      also collect information of the mother and newborn while in the hospital and until discharge
      including de-identified routine ultrasound.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of maternal and perinatal outcomes</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessment of maternal BP trends</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change is being assessed in Maternal Outcomes</measure>
    <time_frame>24 hours</time_frame>
    <description>Assessment of maternal BP trends</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change is being assessed in Maternal Outcomes</measure>
    <time_frame>48 hours</time_frame>
    <description>Assessment of maternal BP trends</description>
  </other_outcome>
  <other_outcome>
    <measure>Change is being assessed in Maternal Outcomes</measure>
    <time_frame>Until delivery</time_frame>
    <description>Assessment of maternal BP trends</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Placental Abruption</measure>
    <time_frame>Baseline until delivery</time_frame>
    <description>Assessment of Placental Abruption</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Pulmonary edema</measure>
    <time_frame>Change from Baseline until delivery</time_frame>
    <description>Assessment of Pulmonary edema</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Acute Kidney Injury</measure>
    <time_frame>Change from Baseline until delivery</time_frame>
    <description>Assessment of Acute Kidney Injury</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of DIC</measure>
    <time_frame>Change from Baseline until delivery</time_frame>
    <description>Assessment of DIC</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of neurological events</measure>
    <time_frame>Change from Baseline until delivery</time_frame>
    <description>Assessment of neurological events</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of laboratory results</measure>
    <time_frame>Change from Baseline until delivery</time_frame>
    <description>Assessment of laboratory results</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Biomarkers</measure>
    <time_frame>Change from Baseline until delivery</time_frame>
    <description>Assessment of Biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Infant Weight</measure>
    <time_frame>Delivery</time_frame>
    <description>Assessment of Infant Weight</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of APGAR score</measure>
    <time_frame>Delivery</time_frame>
    <description>Assessment of APGAR score</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of NICU stays</measure>
    <time_frame>Delivery</time_frame>
    <description>Assessment of NICU stays</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Interventricular hemorrhage</measure>
    <time_frame>Delivery</time_frame>
    <description>Assessment of Interventricular hemorrhage</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Respiratory Distress Syndrome</measure>
    <time_frame>Delivery</time_frame>
    <description>Assessment of Respiratory Distress Syndrome</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Necrotizing enterocolitis (NEC)</measure>
    <time_frame>Delivery</time_frame>
    <description>Assessment of Necrotizing enterocolitis (NEC)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine if the addition of 17 OHPC to the management of Severe PE diagnosed prior to 34 weeks gestation improves maternal and perinatal outcomes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17 OHPC</intervention_name>
    <description>The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Makena, AMAG Pharmaceuticals</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  UMMC antepartum patients with preterm PE between 23 0/7ths and 34 0/7ths weeks
             gestation when initially evaluated

          -  Willing and able to understand study procedures and to provide informed consent

        Exclusion Criteria:

          -  &gt;33 weeks gestational age or &lt;23 weeks gestation

          -  Maternal compromise requiring emergent delivery (ongoing placental abruption, DIC,
             pulmonary edema).

          -  Fetal compromise requiring emergent delivery (fetal bradycardia, recurrent late fetal
             heart rate decelerations, minimal to absent fetal heart rate variability).

          -  Parameters according to current practice guidelines that exclude a patient from
             expectant management include the following:

          -  Preterm premature rupture of membranes (PPROM) &gt; 34 weeks gestation;

          -  Platelet count &lt; 100,000/microliter (thrombocytopenia) with evidence of HELLP
             syndrome;

          -  Persistently abnormal hepatic enzyme concentrations (twice or more upper normal
             values);

          -  Severe fetal growth restriction (ultrasound-estimated fetal weight less than fifth
             percentile);

          -  Severe Oligohydramnios (AFI &lt; 5cm)

          -  Reversal of end diastolic flow(REDF) in umbilical artery Doppler testing;

          -  New onset renal dysfunction or increasing renal dysfunction (serum creatinine &gt; 1.1
             mg/dL;

          -  Recurrent (&gt; 2 readings &gt; 30 minutes apart) severe hypertension despite
             antihypertensive therapy;

          -  Eclampsia;

          -  Pulmonary edema;

          -  Abruption placentae;

          -  Nonreassuring fetal status during daily testing (biophysical profile &lt;4/10 and/or
             recurrent variable or late decelerations);

          -  IUFD
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Babbette LaMarca, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Babbette LaMarca, PhD</last_name>
    <phone>(601)815-1430</phone>
    <email>bblamarca@umc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Winfred L. Wiser Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Babbette LaMarca, PhD</last_name>
      <phone>601-815-1430</phone>
      <email>bblamarca@umc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Venessia Johnson, RN</last_name>
      <phone>(601)984-5328</phone>
      <email>vkjohnson@umc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2016</study_first_submitted>
  <study_first_submitted_qc>December 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>Babbette Lamarca</investigator_full_name>
    <investigator_title>Professor, Obstretrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

